Semaglutide Peptide
Cut six amino acids off the front of a peptide and it got roughly ten thousand times more active. That result, from 1987, is the reason this entire shelf exists.
Choose your pack
For research use only. Not for human or veterinary use.
What Semaglutide Peptide is
The plain-language version, first.
Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist built on the human GLP-1(7-37) backbone, with an Aib substitution at position 8, arginine at position 34, and a C18 diacid acylated to Lys26 through a gamma-glutamate linker and two OEG spacers. Its molecular formula is C187H291N45O59 with a molecular weight of 4113.58, reported GLP-1 receptor affinity of 0.38 nM, and a plasma half-life described as approximately one week.
Here's a thing that shouldn't be true. In 1987 a group published a result on two versions of the same peptide. One of them, GLP-1(1-37), did basically nothing. The other was the same molecule with six residues clipped off the front. It worked at about ten thousand times lower a concentration. > Six amino acids. That was the whole difference. Everything on this shelf downstream of GLP-1 traces back to somebody noticing that. So the field had its molecule. And then it hit a wall, because a peptide that behaves beautifully in a lab prep gets shredded in about two minutes in an actual bloodstream. Semaglutide is the second serious attempt at solving that. A 31-residue analogue of human GLP-1(7-37), with an Aib swap at position 8 so the enzyme that normally cuts it can't get a grip. Then a C18 fatty diacid bolted on, which grabs albumin and refuses to let go. _The molecule was never the hard part. Keeping it around was._
What semaglutide is
Mechanism studied, not outcome promised.
DPP-4 cleaves native GLP-1 between residues 2 and 3 almost instantly. Swapping in alpha-aminoisobutyric acid at position 8 gives the enzyme nothing to grip, which is step one of the entire design.
The C18 diacid binds albumin reversibly. That hides the peptide from renal filtration and it also acts as a depot, since only the unbound fraction is active at any given moment.
Substituting arginine at position 34 removes a competing lysine so the acyl chain attaches at Lys26 and only Lys26. Small edit. Without it the chemistry gets messy fast.
Listen. Your body makes GLP-1 on its own, right now, and it is extremely good at destroying it. Half-life of about two minutes. Your gut releases it, an enzyme called DPP-4 walks up and cuts it, and it's gone before it's finished the job. That's not a bug. That's a signalling molecule doing exactly what a signalling molecule should do, which is shut up quickly. > Which is a problem if you want the signal to last a week instead of a coffee break. So there are two moves here and both are about survival, not activity. One, swap the residue DPP-4 grabs, so the enzyme shows up and finds nothing to hold. Two, hang a fatty tail off it that grips albumin, the most abundant protein in your blood, so the peptide is riding around attached to something the body has no interest in clearing. Here's the honest part. All of that is pharmacokinetics, and pharmacokinetics is knowable, measured and published. What it produces in a person is a clinical question that has been asked properly by people with ethics approval, and their answers belong in their papers. _Not paraphrased on a page that wants your money._
The research so far for Semaglutide Peptide
Where the evidence is thin, we say so.
STEP 1 (NCT03548935, n=1,961, 68 weeks): -14.9% body weight versus -2.4% on placebo. SELECT (NCT03574597, n=17,604): cardiovascular composite hazard ratio 0.80. Approvals from FDA, EMA and Health Canada across several indications, plus the first G7 generic approval in Canada on 28 April 2026. The discovery pharmacology is published in full.
None of that data comes from research-grade material. The trials used pharmaceutical semaglutide under medical supervision. There is no published work supporting any use of research-supplied semaglutide in people, and the FDA has warned companies that illegally sold unapproved drugs containing semaglutide falsely labelled 'for research purposes'.
Semaglutide is the reference compound for albumin-binding acylation. Most of the published work on it sits in large human metabolic and cardiovascular outcome trials rather than in bench pharmacology, which makes it unusual among research peptides: the clinical literature is deeper than the preclinical one.
This is the most heavily documented molecule in the entire catalogue, and it is not close. Receptor pharmacology, pharmacokinetics, a development history going back to 1987, and a regulatory file in multiple countries. > Which is exactly why we are going to say less about it than you might expect.
When a compound has been studied this thoroughly, the temptation is to grab the most impressive number in the file and put it in large type. That is what everybody else selling this does.
The numbers were collected under medical supervision, in trials with entry criteria, on a prescription product. Lifting them onto a page selling research powder changes what they mean.
So: the file is enormous, it is public, and it is worth reading whole. _We will tell you what is in the vial. The papers can tell you the rest._
Canadian stock, cold-shipped from BC. Research use only.
Semaglutide Peptide specs
The chemistry, exactly as released.
Who studies Semaglutide Peptide
Who tends to order this one, and why.
A research compound does not have one audience. It has a handful of rooms where the same question keeps coming up, and the question is a different question in each of them.
Incretin pharmacology researchers
Semaglutide is the reference acylated GLP-1 analogue. If you're comparing a new agonist against something, this is usually the something.
Protein chemists studying acylation
The gamma-glutamate plus two OEG spacer architecture is the template half the field copied afterwards. Useful as a structural comparator.
Receptor and signalling labs
GLP-1R work benefits from a long-acting full agonist with published affinity data behind it. 0.38 nM is a known quantity.
Analytical and method development labs
A 4113.58 dalton peptide with a published formula and CAS number makes a clean subject for mass spec and chromatography method work.
Sold for laboratory research only. This is not guidance for personal use, and nothing here is a recommendation.
Semaglutide Peptide backstory
How it got here.
1987. Svetlana Mojsov and colleagues publish a result on GLP-1 in a perfused rat pancreas. The long form of the peptide does almost nothing. The short form, six residues lighter, triggers insulin release at around 5 x 10^-11 molar. > A ten-thousand-fold gap between two molecules that are nearly the same molecule. Then the field spends years stuck, because the version that works falls apart in minutes in a real bloodstream. Beautiful in a prep. Useless in an animal. Novo's answer arrived in two rounds. Liraglutide came first, carrying a C16 chain, and it got the half-life into daily territory. Semaglutide is the second round. A longer C18 diacid, a spacer, and the position-8 substitution, which together take it from daily to weekly. _Two rounds of chemistry, thirty years apart from the original observation, all of it downstream of somebody clipping six amino acids off the front and looking again._
- 1
1987: six amino acids change everything
Mojsov and colleagues show GLP-1(7-37) triggers insulin release at 5 x 10^-11 M while GLP-1(1-37) is inert. The active hormone gets found, and so does the problem that would define the next thirty years.
- 2
2015: the discovery paper
Lau and colleagues publish the semaglutide discovery in J Med Chem, describing Aib-8, Arg-34, and the C18 diacid on Lys26 that pushes half-life to roughly a week. Receptor affinity is reported at 0.38 nM.
- 3
2024: a Lasker for the fatty acid
Habener, Mojsov and Knudsen share the Lasker-DeBakey award. The citation walks through 1.2 hours, 13 hours, 165 hours, which is the whole acylation story compressed into three numbers.
Buying Semaglutide Peptide in Canada
What ships, how fast, and the paperwork.
The hard part of buying research material is almost never the compound. It is the logistics. What leaves the building, how fast it moves, and what is in the box beside the vial. Here is ours, plainly.
This is not the pharmacy product
Semaglutide is an approved medicine in Canada under several brand names. What we ship is a research material sold for laboratory use, and it is not a substitute for anything a physician prescribes.
Canadian stock, Canadian shipping
Held in Canada and shipped from BC, so it isn't sitting in a customs queue while the cold chain quietly gives up on it.
Read the regulatory picture first
The FDA's GLP-1 page, updated 15 June 2026, says it has warned companies that illegally sold unapproved drugs containing semaglutide falsely labelled 'for research purposes'. Know which side of that line you're on before you order.
Stuff people ask about Semaglutide Peptide
If your question is not here, email us. Real human answers.
Yes. It's a 31-amino-acid peptide built on the human GLP-1(7-37) backbone, with alpha-aminoisobutyric acid at position 8 and arginine at position 34. A C18 fatty diacid is attached to lysine 26 through a gamma-glutamate linker and two OEG spacers. Formula C187H291N45O59, molecular weight 4113.58, CAS 910463-68-2. The acylation is the unusual part, not the backbone.
No, and this mix-up is everywhere. Exendin-4 was isolated from Heloderma suspectum venom by Eng and colleagues in 1992, and that molecule became exenatide. Semaglutide's backbone is human GLP-1 with two substitutions plus a synthetic fatty acid chain. Nobody milked a lizard for it. It was designed at a bench, which is arguably the better story anyway.
Two reasons stacked on each other. The Aib at position 8 blocks DPP-4, the enzyme that clips the front off native GLP-1 within about a minute of it appearing. The C18 diacid then binds albumin, which is too big for the kidney to filter and slow to release its cargo. Together they take the reported half-life to approximately one week.
It is not named on the 2026 WADA Prohibited List, and because multiple regulators have approved it, the S0 catch-all for substances with no regulatory approval doesn't apply either. That's a statement about how the list is written. Athletes should confirm their own status with their sport's anti-doping authority rather than take a product page's word for it.
In everything that matters. Prescription semaglutide is a manufactured drug product, made under pharmaceutical quality systems, dosed and monitored by a clinician, and authorised by Health Canada. This is a research material supplied for laboratory use. The compound name is the same. The product, the oversight and the intended use are not, and we won't blur that.
STEP 1 randomised 1,961 adults with overweight or obesity for 68 weeks and reported a mean weight change of -14.9% versus -2.4% on placebo (Wilding, NEJM 2021). SELECT enrolled 17,604 adults with cardiovascular disease and reported a hazard ratio of 0.80 on the primary cardiovascular composite (Lincoff, NEJM 2023). Both used pharmaceutical semaglutide under medical supervision.
Good pairing options with Semaglutide Peptide
What researchers stack alongside it.
Pairing is where research gets ahead of itself. These are the compounds researchers put in the same order as Semaglutide Peptide, which is a statement about ordering habits, not about evidence. Two things in one cart have not been studied together unless somebody studied them together.
Everything alive builds its peptides from left-handed amino acids. In 1981 a South American tree frog turned up carrying one with a right-handed piece bolted into position two. The whole human record is a single 150-patient trial from 1985.
Cholera taught researchers how the gut's tight junctions swing open. Larazotide is the counter-move, and its phase 3 stopped for futility in 2022. The whole arc is on this page.
Order Semaglutide Peptide right now
One last look before you decide.
Freeze-dried, COA on the page, ships cold
If you are researching Semaglutide Peptide and you want a source you do not have to second-guess, start with the paperwork on this page. For research use only.
Not for human consumption. Not approved by Health Canada or any other regulatory body.
Page last updated August 20, 2026
People also search for Semaglutide Peptide
Other names for the same compound.